Assessment of fluorinated steroids to avert progression and mortality in anti-SSA/Ro-associated cardiac injury limited to the fetal conduction system

Annals of the Rheumatic Diseases

Volumn 75, Issue 6, 2016, Pages 1161-1165

  Izmirly, Peter M ^a   Saxena, Amit ^a   Sahl, Sara K ^a   Shah, Ummara ^b   Friedman, Deborah M ^c   Kim, Mimi Y ^d   Buyon, Jill P ^a  

^a NYU HOSPITAL FOR JOINT DISEASES   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORINATED STEROID; RO ANTIBODY; ANTINUCLEAR ANTIBODY; SS-A ANTIBODIES;

ARTICLE; CHILD; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DISEASE COURSE; ENDOCARDIAL FIBROELASTOSIS; FEMALE; FETUS; FETUS HEART; FETUS HYDROPS; HEART ATRIOVENTRICULAR NODE; HEART BLOCK; HEART MUSCLE CONDUCTION SYSTEM; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PACEMAKER IMPLANTATION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; ADULT; ARTIFICIAL HEART PACEMAKER; BLOOD; COMPLICATION; DIAGNOSTIC IMAGING; EPIDEMIOLOGY; FETAL DISEASES; FETUS ECHOGRAPHY; KAPLAN MEIER METHOD; LUPUS ERYTHEMATOSUS, SYSTEMIC; NEWBORN; PRENATAL CARE; PROCEDURES; REGISTER; UNITED STATES;

ADULT; ANTIBODIES, ANTINUCLEAR; DISEASE PROGRESSION; FEMALE; FETAL DISEASES; HEART BLOCK; HUMANS; INFANT, NEWBORN; KAPLAN-MEIER ESTIMATE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PACEMAKER, ARTIFICIAL; PRENATAL CARE; REGISTRIES; RETROSPECTIVE STUDIES; STEROIDS, FLUORINATED; ULTRASONOGRAPHY, PRENATAL; UNITED STATES;

EID: 84954285221     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-208311     Document Type: Article

References (20)

1. Llanos C, Friedman DM, Saxena A, et al. Anatomical and pathological findings in hearts from fetuses and infants with cardiac manifestations of neonatal lupus. Rheumatology (Oxford) 2012;51:1086-92.
2. Moak JP, Barron KS, Hougen TJ, et al. Congenital heart block: development of late-onset cardiomyopathy, a previously underappreciated sequela. J Am Coll Cardiol 2001;37:238-42.
3. Nield LE, Silverman ED, Taylor GP, et al. Maternal anti-Ro and anti-La antibody-associated endocardial fibroelastosis. Circulation 2002;105:843-8.
4. Brito-Zerón P, Izmirly PM, Ramos-Casals M, et al. The clinical spectrum of autoimmune congenital heart block. Nat Rev Rheumatol 2015;11:301-12.
5. Izmirly PM, Saxena A, Kim MY, et al. Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus. Circulation 2011;124:1927-35.
6. Eliasson H, Sonesson SE, Sharland G, et al. Isolated atrioventricular block in the fetus: a retrospective, multinational, multicenter study of 175 patients. Circulation 2011;124:1919-26.
7. Marciniak B, Patro-Malysza J, Poniedzialek-Czajkowska E, et al. Glucocorticoids in pregnancy. Curr Pharm Biotechnol 2011;12:750-7.
8. Saleeb S, Copel J, Friedman D, et al. Comparison of treatment with fluorinated glucocorticoids to the natural history of autoantibody-associated congenital heart block: retrospective review of the research registry for neonatal lupus. Arthritis Rheum 1999;42:2335-45.
9. Breur JM, Visser GH, Kruize AA, et al. Treatment of fetal heart block with maternal steroid therapy: case report and review of the literature. Ultrasound Obstet Gynecol 2004;24:467-72.
10. Friedman DM, Kim MY, Copel JA, et al. Prospective evaluation of fetuses with autoimmune-associated congenital heart block followed in the PR Interval and Dexamethasone Evaluation (PRIDE) Study. Am J Cardiol 2009;103:1102-6.
11. Jaeggi ET, Fouron JC, Silverman ED, et al. Transplacental fetal treatment improves the outcome of prenatally diagnosed complete atrioventricular block without structural heart disease. Circulation 2004;110:1542-8.
12. Lopes LM, Tavares GM, Damiano AP, et al. Perinatal outcome of fetal atrioventricular block: one-hundred-sixteen cases from a single institution. Circulation 2008;118:1268-75.
13. Costedoat-Chalumeau N, Amoura Z, Le Thi Hon D, et al. Questions about dexamethasone use for the prevention of anti-SSA related congenital heart block. Ann Rheum Dis 2003;62:1010-12.
14. National Institutes of Health Consensus Development Panel. Antenatal corticosteroids revisited: repeat courses - National Institutes of Health Consensus Development Conference Statement, August 17-18, 2000. Obstet Gynecol 2001;98:144-50.
15. Buyon JP, Hiebert R, Copel J, et al. Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol 1998;31:1658-66.
16. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.
17. Eronen M, Siren MK, Ekblad H, et al. Short- and long-term outcome of children with congenital complete heart block diagnosed in utero or as a newborn. Pediatrics 2000;106:86-91.
18. Jaeggi ET, Hamilton RM, Silverman ED, et al. Outcome of children with fetal, neonatal or childhood diagnosis of isolated congenital atrioventricular block. A single institution's experience of 30 years. J Am Coll Cardiol 2002;39:130-7.
19. Slikker W, Althaus ZR, Rowland JM, et al. Comparison of the transplacental pharmacokinetics of cortisol and triamcinolone acetonide in the rhesus monkey. J Pharmacol Exp Ther 1982;223:368-74.
20. Mason JW, O'Connell JB, Herskowitz A, et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med 1995;333:269-75.